CONTINUING MEDICAL EDUCATION
Imedex, LLC designates this educational activity for a maximum of 12.00 of AMA PRA Category 1 Credits™.  Physician should only claim credit commensurate with the extent of their participation in the activity.

 

WHO SHOULD ATTEND
This educational activity is primarily targeted to academic and community hematologists and oncologists, and secondarily to oncology nurses and other health care professionals interested in the management of patients with hematologic malignancies.

 

OBJECTIVES
After successful completion of this course, attendees should be able to:
-Evaluate and compare current treatment options for newly diagnosed transplant ineligible patients with multiple myeloma
-Compare and contrast the various therapeutic options for patients with relapsed multiple myeloma
-Discuss the pros and cons of stem cell transplantation for patients with multiple myeloma
-Discuss the evolving science of molecular oncology and genomics as it applies to hematologic malignancies
-Describe the emerging novel agents for B-cell and T-cell non-Hodgkins lymphoma
-Discuss therapeutic options for first line therapy of diffuse large B-cell lymphoma
-Evaluate and discuss the emerging role of radioimmunotherapy in follicular lymphoma
-Develop and plan appropriate management strategies for patients with mantle cell lymphoma
-Describe and discuss the role of emerging therapies for both low risk and high risk patients with myelodysplastic syndromes
-Recognize and relate the evolving understanding and emerging therapies for myeloproliferative disorders
-Compare and contrast the various treatment options for chronic myelocytic leukemia
-Evaluate the role of various treatment regimens in the management of chronic lymphocytic leukemia
-Evaluate and discuss the most appropriate treatment options for patients with AML
-Describe and discuss novel emerging therapies for acute myelocytic leukemia

Stephen M. Ansell, MD, PhD Mayo Clinic Rochester, Minnesota Asher A. Chanan-Khan, MD Roswell Park Cancer Institute Buffalo, New York Marcel P. Devetten, MD University of Nebraska Medical Center Omaha, Nebraska Stefan Faderl, MD The University of Texas M. D. Anderson Cancer Center Houston, Texas Richard I. Fisher, MD University of Rochester Medical Center Rochester, New York Christopher R. Flowers, MD, MS Winship Cancer Institute Atlanta, Georgia Rafael Fonseca, MD Mayo Clinic Scottsdale, Arizona

Jonathan Friedberg, MD University of Rochester Medical Center Rochester, New York Sergio Giralt, MD The University of Texas M. D. Anderson Cancer Center Houston, Texas Timothy C. Greiner, MD University of Nebraska Medical Center Omaha, Nebraska Frederick B. Hagemeister, MD The University of Texas M. D. Anderson Cancer Center Houston, Texas Sagar Lonial, MD Winship Cancer Institute Atlanta, Georgia Michael Mauro, MD Oregon Health & Science University Portland, Oregon S. Vincent Rajkumar, MD Mayo Clinic Rochester, Minnesota

Gail J. Roboz, MD Weill Medical College of Cornell University Ithaca, New York Charles Schiffer, MD Barbara Ann Karmanos Cancer Institute Detroit, Michigan Gary Schiller, MD UCLA Medical Center Los Angeles, California David Steensma, MD Mayo Clinic Rochester, Minnesota Moshe Talpaz, MD University of Michigan Health System Ann Arbor, Michigan Ayalew Tefferi, MD Mayo Clinic Rochester, Minnesota Steven P. Treon, MD, PhD Dana-Farber Cancer Institute Boston, Massachusetts

Friday, September 19th, 2008

8:00 am
Introductions

CML
8:10 am
Debate: How should we monitor CML response today – the role of FISH, Q-PCR, mutations?
Minimal monitoring – Stefan Faderl, MD
Substantial monitoring – Michael Mauro, MD

8:30 am
Lecture: Defining imatinib failure and deciding when to intervene with a second generation TKI
Michael Mauro, MD

8:55 am
Debate: Is allogeneic SCT the second line therapy of choice following resistance to imatinib?
Yes: Sergio Giralt, MD
No: Stefan Faderl, MD

9:20 am
Lecture: T315I – how common, how serious, how treatable?
Moshe Talpaz, MD

9:45 am
Lecture: Are there newly diagnosed CP-CML patients for whom single agent imatinib is not adequate therapy?
Charles Schiffer, MD

10:10 am
Break

Myeloproliferative Disorders
10:20 am
Lecture: JAK2 Inhibitors: Hope or hype
Ayalew Tefferi, MD

Acute Leukemia
10:45 am
Debate: What is the best therapeutic option for elderly AML?
Intensive therapy – Gary Schiller, MD
Low intensity therapy – Hagop M. Kantarjian, MD

11:10 am
Lecture: Novel agents in clinical trials for acute leukemia
Hagop M. Kantarjian, MD

11:35 am
Debate: What is the role of BMT in adult AML?
BMT should be the primary option in first CR – Sergio Giralt, MD
BMT does not benefit AML over standard chemotherapy – Charles Schiffer, MD

12:00 pm
Lunch

CLL
12:45 pm
Lecture: Richter’s Syndrome – Risk, management and prognosis
James  O. Armitage, MD

1:15 pm
Lecture: Integrating bendamustine into the treatment algorithm for CLL
Jonathan Friedberg, MD

1:40 pm
Lecture: Targeting BCL-2 in CLL
Asher Chanan-Khan, MD

2:05 pm
Lecture: Managing relapsed/refractory CLL following fludarabine-based therapy
Asher Chanan-Khan, MD

2:30 pm
Break

Myelodysplasia
2:50 pm
Debate: Should the IPSS be changed given the greater prognostic impact of cytogenetic abnormalities, transfusions and other factors?

IPSS is still the best standard
Gail J. Roboz, MD

IPSS should be modified
Marcel P. Devetten, MD

3:15 pm
Lecture: Hypomethylating agents, HDAC inhibitors and their combinations in MDS
Gail J. Roboz, MD

3:45 pm
Adjourn

Saturday, September 20th, 2008
Myelodysplasia (continued)
8:10 am
Debate: What is the preferred therapeutic option for high
risk MDS?
Allo SCT is the best option – David Steensma, MD
Epigenetic therapy is the best option – Marcel P. Devetten, MD

8:35 am
Lecture: Maximizing the benefits, minimizing the risk in IMiD therapy for MDS – which patients and which dose schedules are most appropriate
David Steensma, MD

Hodgkin’s Lymphoma
9:00 am
Lecture: The role of baseline and interval PET scans in the management of early stage Hodgkin’s Lymphoma
Frederick B. Hagemeister, MD

9:25 am
Break

Non-Hodgkins Lymphoma
9:45 am
Lecture: Prognostic stratification of lymphomas through molecular biology
Timothy C. Greiner, MD

10:10 am
Debate: Chemotherapy versus chemo-radiotherapy for early stage DLBCL – should the decision be based on the results of post-chemotherapy PET scans?
Yes: Frederick B. Hagemeister, MD
No: Christopher R. Flowers, MD, MS

10:35 am
Debate: Should advanced stage FL patients receive consolidation therapy with RIT following initial response to systemic chemotherapy?
Yes: Christopher R. Flowers, MD, MS
No: Jonathan Friedberg, MD

11:00 am
Lecture: Novel systemic therapies for lymphoma
Richard I. Fisher, MD

11:30 am
Lunch

12:15 pm
Debate: Should patients with high risk FL receive anthracycline based frontline therapy?
Yes: Stephen M. Ansell, MD, PhD
No: Richard I. Fisher, MD

12:40 pm
Lecture: Management strategies for gastric MALT lymphoma that is either H. pylori negative or antibiotic resistant
Stephen M. Ansell, MD, PhD

Myeloma
1:05 pm
Lecture: Evolution & revolution in the management
of multiple myeloma
Steven P. Treon, MD, PhD

1:30 pm
Lecture: Free light chains – their role in prognosis and monitoring of myeloma
Sagar Lonial, MD

1:55 pm
Break

2:15 pm
Debate: Should newly diagnosed myeloma patients, who achieve an immunofixation negative CR with novel frontline therapy, be referred for SCT in first remission or should SCT be delayed until disease progression?
Yes: Robert Z. Orlowski, MD
No: Rafael Fonseca, MD

2:40 pm
Lecture: AL amyloidosis – new interest & new options
S. Vincent Rajkumar, MD

3:05 pm
Lecture: Emerging novel therapies for plasma cell dyscrasias
Rafael Fonseca, MD

3:30 pm
Debate: How should newly diagnosed high risk patients with poor risk cytogenetics be managed?

SCT
S. Vincent Rajkumar, MD

Clinical trials with novel agents
Robert Z. Orlowski, MD, PhD

4:00 pm
Adjourn

REGISTRATION FEES
Discounted . . . . . . . . . . . . . . .$150
If payment received by September 11, 2008

Full . . . . . . . . . . . . . . . . . . . . $250
If payment received after September 11, 2008

Nurses, Fellows, Residents . . . . $75

To Register: You may register online by September 11, 2008 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To pre-register, registration and payment must be received no later than September 11, 2008. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. An attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex no later than September 11, 2008. The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after September 11, 2008.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

Wyndham Chicago
633 North St. Clair Street
Chicago, Illinois 60611
Tel.: +1 (312) 573 0300
Fax: +1 (312) 274 0164
Website: http://www.wyndham.com/groupeventsnew/orddt_greatdebatesinhemo/main.wnt

The Wyndham Chicago is an oasis of comfort and style in the heart of Chicago’s Magnificent Mile. Just one block off Michigan Avenue in a neighborhood full of world-class restaurants, shopping, museums and galleries. Lake Michigan, the Symphony Center and the Loop financial district are all nearby.

Settle into a spacious room or suite with a dazzling view of downtown Chicago. Enjoy thoughtful touches like high-speed Internet access and a cordless multi-line phone. Dine at the chic Caliterra Bar & Grille or unwind in the fitness center and indoor pool. Relax with a walk through our vibrant neighborhood - or let the concierge plan a special outing.

For the convenience of attendees, a limited number of rooms have been reserved until August 29, 2008 at a discounted rate of $279 single/double occupancy, plus tax, currently at 15.4%. This rate is not guaranteed outside the conference dates or after August 29, 2008.

To reserve your room please contact the Wyndham Chicago reservations department at +1 (312) 573 0300 or visit the hotel’s website. To receive the group rate, callers must identify themselves as being with the Great Debates in Hematology group. Reservation requests received after August 29, 2008 may not be guaranteed the group rate.

The following companies have provided an unrestricted educational grant in support of this conference:

 

Gold   Silver   Corporate Genentech BioOncology and Biogen Idec

 

Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1 (770) 751 7332, or by email at CME@imedex.com.